Prostate-Specific Antigen
"Prostate-Specific Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
| Descriptor ID |
D017430
|
| MeSH Number(s) |
D08.811.277.656.300.760.442.750 D08.811.277.656.959.350.442.750 D12.776.866.249.500 D23.050.285.625 D23.101.140.625
|
| Concept/Terms |
Prostate-Specific Antigen- Prostate-Specific Antigen
- gamma-Seminoprotein
- gamma Seminoprotein
- Prostate Specific Antigen
- hK3 Kallikrein
- Kallikrein, hK3
- Semenogelase
- Kallikrein hK3
- Seminin
|
Below are MeSH descriptors whose meaning is more general than "Prostate-Specific Antigen".
Below are MeSH descriptors whose meaning is more specific than "Prostate-Specific Antigen".
This graph shows the total number of publications written about "Prostate-Specific Antigen" by people in this website by year, and whether "Prostate-Specific Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 2 | 3 |
| 1997 | 0 | 3 | 3 |
| 1998 | 1 | 3 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 5 | 1 | 6 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 2 | 3 |
| 2003 | 2 | 11 | 13 |
| 2004 | 4 | 4 | 8 |
| 2005 | 2 | 4 | 6 |
| 2006 | 2 | 2 | 4 |
| 2007 | 1 | 7 | 8 |
| 2008 | 2 | 5 | 7 |
| 2009 | 4 | 2 | 6 |
| 2010 | 1 | 5 | 6 |
| 2011 | 3 | 6 | 9 |
| 2012 | 4 | 4 | 8 |
| 2013 | 0 | 4 | 4 |
| 2014 | 0 | 4 | 4 |
| 2015 | 3 | 3 | 6 |
| 2016 | 1 | 4 | 5 |
| 2017 | 0 | 2 | 2 |
| 2018 | 1 | 4 | 5 |
| 2019 | 2 | 5 | 7 |
| 2020 | 0 | 2 | 2 |
| 2021 | 1 | 4 | 5 |
| 2022 | 1 | 3 | 4 |
| 2023 | 1 | 4 | 5 |
| 2024 | 2 | 1 | 3 |
| 2025 | 1 | 3 | 4 |
| 2026 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Prostate-Specific Antigen" by people in Profiles.
-
Efficacy, Safety, and Cost-Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non-Metastatic Castration-Resistant Prostate Cancer: A Multicenter Retrospective Study. Prostate. 2026 Aug; 86(11):1233-1240.
-
Cross-resistance among novel androgen receptor signaling inhibitors in non-metastatic castration-resistant prostate cancer. Int J Clin Oncol. 2025 Dec; 30(12):2635-2642.
-
Phase 3 Trial of Dose-Escalated Radiation Therapy and Standard Androgen Deprivation Therapy Versus Dose-Escalated Radiation Therapy and Enhanced Androgen Deprivation Therapy With Orteronel for Men With High-Risk Prostate Cancer (NRG/RTOG 1115). Int J Radiat Oncol Biol Phys. 2025 Dec 01; 123(5):1247-1258.
-
Testosterone replacement therapy in men on active surveillance for prostate cancer. J Sex Med. 2025 04 08; 22(3):432-438.
-
HDR brachytherapy salvage for nodular prostate fossa recurrence: A mechanistic review and initial report of clinical outcomes. Brachytherapy. 2025 May-Jun; 24(3):404-412.
-
Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Netw Open. 2024 10 01; 7(10):e2437871.
-
Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone-sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide. Eur Urol Oncol. 2024 Oct; 7(5):1097-1104.
-
A west African ancestry-associated SNP on 8q24 predicts a positive biopsy in African American men with suspected prostate cancer following PSA screening. Prostate. 2024 May; 84(7):694-705.
-
Prostate-Specific Antigen Response to Androgen Deprivation Therapy in the Neoadjuvant Setting for High-Risk Prostate Adenocarcinoma (PIRANHA): Pooled Analysis of Two Randomized Clinical Trials. Int J Radiat Oncol Biol Phys. 2024 07 01; 119(3):826-831.
-
Prostate Safety Events During Testosterone Replacement Therapy in Men With Hypogonadism: A Randomized Clinical Trial. JAMA Netw Open. 2023 12 01; 6(12):e2348692.